oxybutynin(redirected from Kentera)
Also found in: Dictionary.
Related to Kentera: Ditropan, Lyrinel, Oxytrol
Cystrin (UK), Kentera (UK), Oxytrol
Pharmacologic class: Anticholinergic
Therapeutic class: Urinary tract antispasmodic
Pregnancy risk category B
Inhibits acetylcholine action at postganglionic receptors, relaxing smooth muscle lining of GU tract and preventing bladder irritability
Syrup: 5 mg/5 ml
Tablets: 5 mg
Tablets (extended-release): 5 mg, 10 mg, 15 mg
Topical gel: 1 g in 1.14-ml sachet
Transdermal system (patch): 39 cm2/36 mg
⊘Indications and dosages
➣ Frequent urination, urinary urgency or incontinence, and nocturia caused by neurogenic bladder; overactive bladder
Adults: 5 mg P.O. two to three times daily (not to exceed 5 mg q.i.d.); or 5 to 15 mg P.O. once daily (extended-release); or one 3.9 mg/day transdermal system applied twice weekly; or apply contents of one gel sachet daily.
Children older than age 5: 5 mg P.O. b.i.d., to a maximum of 5 mg t.i.d.
• Elderly patients
• Hypersensitivity to drug
• Intestinal obstruction, severe colitis, atony, paralytic ileus, megacolon, or hemorrhage
• Obstructive uropathy, urinary retention
• Myasthenia gravis
• Acute hemorrhage with shock
Use cautiously in:
• cardiovascular disease, hyperthyroidism, GI disease
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 5 (safety not established).
• Give oral forms without regard to food.
• Don't crush or break tablets.
• Apply contents of one gel sachet to dry, intact skin on the abdomen, upper arms, shoulders, or thighs.
CNS: dizziness, drowsiness, hallucinations, insomnia, weakness, anxiety, restlessness, headache
CV: palpitations, hypotension, tachycardia
EENT: blurred vision, cycloplegia, increased intraocular pressure, mydriasis, photophobia
GI: nausea, vomiting, diarrhea, constipation, bloating, dry mouth
GU: urinary hesitancy, urinary retention, erectile dysfunction, suppressed lactation
Skin: decreased sweating, urticaria, application-site reactions
Other: allergic reactions, fever, hot flashes
Drug-drug.Anticholinergics, anticholinergic-like drugs (including amantadine, antidepressants, disopyramide, haloperidol, phenothiazines): additive anticholinergic effects
Atenolol: increased atenolol absorption
CNS depressants (including antidepressants, antihistamines, opioids, sedative-hypnotics): additive CNS depression
Digoxin: increased digoxin blood level (with extended-release oxybutynin)
Haloperidol: decreased haloperidol blood level, tardive dyskinesia, worsening of schizophrenia
Levodopa: decreased levodopa efficacy
Nitrofurantoin: increased nitrofurantoin blood level, greater risk of toxicity
Drug-herbs.Angel's trumpet, jimsonweed, scopolia: increased anticholinergic effects
Drug-behaviors.Alcohol use: additive CNS depression
• Monitor vital signs and temperature. Watch for hypotension, fever, and tachycardia.
• Evaluate patient's vision.
• Assess results of cystometric studies. Stay alert for urinary retention.
• Tell patient he may take with or without food. Caution him not to crush, break, or chew extended-release tablets.
• Instruct patient to apply transdermal patch to dry, intact skin on abdomen, hip, or buttock. Tell him to use a new skin area with each new system and not to reapply new patch to same site within 7 days. Caution him not to cut or puncture patch.
• Instruct patient to apply contents of one gel sachet daily to dry, intact skin on the abdomen, upper arms, shoulders, or thighs. Tell patient to use a new skin area daily. Advise patient to cover application site with clothing if skin-to-skin contact at application site is anticipated and to wash hands immediately after product application. Warn patient that gel is flammable and to avoid open fire or smoking until gel has dried.
• Tell patient to report blurred vision, fever, skin rash, nausea, or vomiting.
• Advise patient he'll need to undergo periodic bladder exams.
• Caution patient to avoid driving and other hazardous activities if drug causes drowsiness or blurred vision.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.